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Head and neck neoplasms have a poor prognosis because of their late diagnosis. Finding
a biomarker to detect these tumors in an early phase could improve the prognosis
and survival rate. This literature review provides an overview of biomarkers, covering
the different -omics fields to diagnose head and neck neoplasms in the early phase.
To date, not a single biomarker, nor a panel of biomarkers for the detection of head
and neck tumors has been detected with clinical applicability. Limitations for the clinical
implementation of the investigated biomarkers are mainly the heterogeneity of the study
groups (e.g., small population in which the biomarker was tested, and/or only including
high-risk populations) and a low sensitivity and/or specificity of the biomarkers under
study. Further research on biomarkers to diagnose head and neck neoplasms in an early
stage, is therefore needed.
Keywords: head and neck neoplasms, biomarker, genomics, proteomics, metabolomics, volatomics,
microbiomics, radiomics
INTRODUCTION
Head and neck cancers account for 5% of all malignant tumors and are responsible for about
600,000 new cases and 300,000 deaths in the world annually. About 50% of the patients fail to
achieve cure and cancer relapse occurs despite intensive combined treatment (1, 2). To date, there is
no adequate biomarker available for the diagnosis of head and neck cancer. However, it is expected
that an earlier detection could improve the patient’s outcome stage (3–7). In this review, we provide
a general overview of biomarkers that were investigated to diagnose head and neck neoplasms in
an early phase. Besides, we go into detail on the restrictions of these candidate biomarkers in the
clinical practice.
Head and neck neoplasms are defined as benign, premalignant and malignant
tumors above the clavicles, with exception of tumors of the brain, and spinal cord
and esophagus (2). This includes tumors of the paranasal sinus, the nasal cavity, the
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salivary glands, the thyroid, and the upper aerodigestive tract
(oral cavity, pharynx, and larynx) (8, 9). Carcinomas of the head
and neck preferably metastasize lymphogenic to the regional
lymph nodes and it is only in an advanced stage that they
metastasize hematogenic to the lungs, liver, and bones (1). The
histopathology of the cancers differs from site to site, but the
most common ones are squamous cell carcinomas, accounting
for more than 85% of the head and neck neoplasms (8, 9).
There are several known risk factors for the development
of head and neck carcinomas. Prolonged exposure to the sun
has been shown to be partly responsible for the genesis of
skin and lip cancer (2). Epstein-Barr virus infection, living in
a smoky environment and eating raw salted fish are important
risk factors in the development of a nasopharyngeal carcinoma
(1, 8). Infection with human papilloma virus plays a significant
role in the genesis of oropharyngeal cancer (8). Carcinomas of
the paranasal sinuses are more frequently seen in woodworkers;
particularly tropical hardwood forms an important trigger (1).
Chewing betel nut, especially in Asia, plays a major role in
the etiology of cancer of the oral cavity (1). Excessive use of
tobacco and alcohol inducesmucosal changes of the aerodigestive
tract. These alterations play an important role in the genesis
of malignant tumors (1, 8). Besides tobacco and alcohol, other
factors influence mucosal changes like nutritional deficiencies (in
particular vitamin A and vitamin C in the context of insufficient
intake of fresh fruits and vegetables) and genetic predisposition
(1, 8). In the development of tumors of the skin, mucosa,
thyroid gland, parathyroid glands and the salivary glands, former
exposure to ionizing radiation might also be of influence (2).
In comparison with other malignant tumors, head, and neck
neoplasms are not common in the Western world. However,
a rapid increase of the incidence of oropharyngeal cancers
related to HPV in developed countries, has been shown (8).
Although this incidence (and therefore the mortality rate) is
lower compared to other cancers, patients with head and neck
cancer have a poor prognosis, mainly due to the fact that these
types of cancers are usually diagnosed at an advanced stage (3–
7). One-third of the patients gets medical care in an early stage,
while two-third are only diagnosed when they already entered an
advanced stage (1). According to the WHO, the most common
sites of head and neck neoplasms are the oral cavity, the larynx
and the pharynx (8). The highest incidence of head and neck
cancer is seen in South East Asia (8). Head and neck neoplasms
are more prevalent in men than women and they most likely
appear in the age range of 60–80 years. The average age of
diagnosis is 62 years for men and 63 years for women (1).
METHODS
Literature was searched through MEDLINE (PubMed Database).
The search started in October 2017 and was limited to papers
published in the last decade. The last database search was
performed on March 31st, 2019. A combination of the following
Mesh terms was used: “biomarkers, tumor”; “head and neck
neoplasms”; “early diagnosis”; “volatile organic compounds”;
“microbiota”; “papillomaviridae”; “radiomics,” leading to 247
articles. Based on the title and abstract, we selected 148 articles
and after reading the full texts and assessing the quality of the
texts, we eventually ended up with 102 articles on this topic. The
quality of the studies was assessed by three researchers (SS, HK,
and MG). To broaden our search and complete our electronic
query, reference lists of articles already withheld, were also
verified. Six more articles were included through this snowball
method. In total, 108 articles were included in this review. The
selection procedure is displayed in a flow diagram (Figure 1).
RESULTS
Since head and neck cancers have a poor prognosis and are
most frequently diagnosed at an advanced stage, finding a
biomarker for early diagnosis of these tumors, is of tremendous
importance to reduce morbidity and mortality (3, 10). Therefore,
several biomarkers have been investigated so far. We provide
a general overview of known biomarkers for diagnosis of
head and neck neoplasms, including a discussion of the most
promising markers. Strictly speaking, cancers of the upper part
of the esophagus are also part of the head and neck tumors.
In this literature review, however, they were not included. In
Tables 1–8, all the investigated diagnostic markers with brief
additional information are presented. More details about the
biomarkers with their restrictions and advantages are provided
in the Supplementary Tables 1–5. In the following paragraphs,
we will discuss and present the biomarkers based on the
applied -omics approach (genomics, proteomics, metabolomics,
glycomics, volatomics, microbiomics, and radiomics).
Genomics
In the genomic approach, various methods were used to analyze
genetic aberrations such as DNA sequencing, single nucleotide
polymorphism analysis and hybridization techniques. Changes
in gene expression are considered as a potential biomarker.
A benefit of this approach is that it might also reveal the
disease’s underlying cause. On the other hand, there are also
some demerits. Cancer is a condition in which many genes
interact. Therefore, a single biomarker is probably insufficient
to diagnose head and neck cancer and a biomarker panel
of genes is recommended. It might also be unclear which
post-transcriptional regulatory processes are involved (70).
Table 1 and Supplementary Table 1 summarize the biomarkers
involving genomics.
Promoter Hypermethylation
Promoter hypermethylation refers to the epigenetic process of
abnormal methylation of CpG-islands in the promoter region.
The promoter regions of genes initiate gene transcription and
are usually not methylated (12). These alterations are associated
with gene silencing in cancer (14). Methylation is suggested
to be an early event in carcinogenesis (3, 14), which makes
it an interesting candidate as a biomarker. In this manner,
early diagnosis is potentially achieved and consequently leads
to a better prognosis. Different papers focused on promoter
hypermethylation and show that specific genes of patients
with head and neck neoplasms have a higher prevalence of
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FIGURE 1 | Flow diagram of article selection.
methylation in comparison to a healthy control group (3, 6, 11,
12). Sushma et al. suggest a promoter hypermethylation panel for
oral squamous cell carcinoma (OSCC) consisting of the following
genes: PTEN and p16 (12), which can be detected by a tissue
biopsy. Guerrero et al. also suggest a promoter hypermethylation
panel for detection of OSCC with the genes HOXA9 and NID2,
identified via tissue biopsy or salivary rinses (3). However, despite
a high specificity of promoter hypermethylation as a biomarker,
its sensitivity was low. Using a panel of genes increased the
sensitivity but came at the cost of a lowered specificity. Moreover,
in these studies, the included population was small and/or
consisted of high-risk patients. Further research would thus be
necessary to explore this potential marker.
Epstein-Barr Virus DNA Load
Nasopharyngeal carcinoma is closely associated with a latent
Epstein-Barr virus (EBV) infection (13, 71). The EBV DNA
load has biomarker potential [sensitivity of 95% (95% CI, 91–
98%), specificity of 98% (95% CI, 96–99%) (14)]. The serum
concentration correlates to the tumor burden, resulting in a low
specificity in early tumor stages but pointing toward the potential
of a good prognostic biomarker (high concentrations indicating a
greater tumor mass and thus negative prognosis). A combination
of the EBV DNA load with a marker for early detection
would increase the sensitivity for an early stage detection of
nasopharyngeal carcinoma. Yang et al. therefore suggested to
combine EBV DNA load with a panel of hypermethylation
markers for detection of nasopharyngeal carcinoma (13), since
methylation is an early event in carcinogenesis (3, 13).
Several antibodies to EBV were also investigated as a
biomarker for the diagnosis of nasopharyngeal carcinoma, for
example anti-EBV capsid antigen IgA (IgA-VCA) (71). This is
further discussed under the paragraph “proteomics.” Epstein-
Barr virus DNA load [95% (95% confidence interval, 91–
98%)] and IgA-VCA [sensitivity of 81% (95% CI, 73–87%)] are
two of the most sensitive biomarkers found in the peripheral
blood of nasopharyngeal carcinoma patients. When combined,
a sensitivity of 99% was obtained. The specificity of EBV
DNA and IgA-VCA was 98% (96–99%) and 96% (91–98%),
respectively. On top of this, because of their different production
mechanism, the combination of both markers could minimize
false positive cases (14). With its high sensitivity and specificity,
this biomarker panel of EBV DNA and IgA-VCA seems very
promising in the diagnosis of nasopharyngeal carcinoma. Further
prospective validation studies in independent cohorts are needed
for confirmation and determination of its position in the
diagnostic landscape.
Human Papillomavirus DNA Load
As already mentioned, human papillomavirus (HPV) and
Epstein-Barr virus (EBV) are identified viral risk factors for
head and neck neoplasms (72). Since HPV-16 accounts for
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TABLE 1 | Summary of genomics in head and neck neoplasms.
Studied marker Type of tumor No. of
patients
























OSCC 50 Tissue biopsy ↓ – (12)
EBV DNA load +
hypermethylation panel
(RASSF1A, WIF1, DAPK1, and
RARβ2)














IgA VCA + EBV DNA load NPC 139 Blood sample ↑ 99% 96–98% – (14)
miRNA
Combination of miR-196a and
miR-196b








LSCC 20 Blood sample ↑ – (7)




39 Tissue biopsy ↓/↑ 86.21% 100% – (15)
miR-155 LSCC 280 Tissue biopsy,
blood sample
↑ 58.4% 69.5% – (17)
INTERFERONS
Interferon inducible
transmembrane protein 1 (IFITM1)
OSCC 38 Tissue biopsy ↑ – (18)




OSCC 70 Brush biopsy ↑ – (20)
UPREGULATED GENES
ADAM15, CDC7, IL12RB2, and
TNFRSF8
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TABLE 1 | Continued






HPV-16 E6 antibodies OPC (HPV
driven (n = 5)
and non-HPV
driven [n = 4)]






– 100% (95% CI
= 40–100%)
–
HPV-16 E6 antibodies OPSCC (HPV
driven)







HPV-16 E6 antibodies HNSCC
(excluding OPC)







HPV-16 E7 HNSCC (HPV
driven)
30 Blood sample Seropositive – – – (24)
Saliva sample – – –
OTHERS




27 Blood sample ↑ – (26)
EBV, Epstein-Barr virus; HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; LSCC, laryngeal squamous cell carcinoma; miRNA, microRNA; NPC,
nasopharyngeal carcinoma; OL, oral leukoplakia; OPC, oropharyngeal carcinoma; OPSCC, oropharyngeal squamous cell carcinoma; OSCC, oral squamous cell carcinoma.
>90% of HPV-DNA positive head and neck squamous cell
carcinomas (HNSCC), it is regarded as the predominant
HPV type in these specific malignancies (73). As a result,
this is currently the only HPV type that has been studied
in HNSCC.
The oral HPV-16 prevalence in healthy individuals is ∼1%,
suggesting HPV sequences could be used as a biomarker to detect
the associated neoplasms (73). An important association has
been demonstrated between HPV and oropharyngeal squamous
cell carcinomas (OPSCC) on the one hand and some non-
oropharyngeal head and neck squamous cell carcinomas on
the other hand such as cancers of the oropharynx, larynx,
and hypopharynx (73). In general, the survival rate was found
to be higher for tumors that were HPV-positive compared
to the neoplasms that were HPV-negative (24), stressing the
prognostic property. Besides this classification, tumors can also
be divided in HPV-driven and non-HPV-driven cancer. HPV-
driven malignancies are, amongst other things, characterized
by at least one HPV genome copy per tumor cell, as
opposed to non-HPV-driven malignancies which express only
low copy numbers of HPV DNA (23). Holzinger et al. state
that HPV-driven OPSCC are classified as a distinct tumor
entity and have specific characteristics, of which a better
patient survival is of the biggest clinical importance (23). In
contrast, patient survival in HPV-positive but non-HPV-driven
OPSCC is similar to that of patients with HPV-negative cancer
(23). Kreimer et al. showed, in a small subset of tumor
specimens (n = 9), that the sensitivity of antibodies to HPV-
16 oncoprotein E6 (HPV-16 E6) for detection of HPV-driven
OPC in blood, was exceptionally high (estimated at 100%,
95% CI = 47.8–100%) with a specificity that was also in
this range (estimated at 100%, 95% CI = 39.8–100%) (22).
Holzinger et al. supported this statement and showed that
HPV-16 E6 seropositivity had a very high sensitivity (96%)
and specificity (98%) to diagnose HPV-driven OPSCC. In
contrast, the sensitivity for diagnosis of HNSCC excluding
oropharyngeal carcinoma, was much lower (50%, 95% CI
= 19–81%) despite the very high specificity (100%, 95%
CI= 96–100%) (23).
Regarding sampling methods, HPV DNA load, and HPV
antibodies can be detected in plasma as well as in saliva (23,
24, 26, 72). Wang et al. demonstrated that HPV DNA could be
detected in the plasma of 86% of the patients, compared to only
40% of the saliva of these same patients, indicating that plasma
would be more informative to diagnose HPV-associated tumors
despite the need for invasive sampling (24). Indeed, Kreimer et al.
found that in OPSCC, the sensitivity for HPV-16 DNA detection
in saliva was found to be between 45 and 82% compared to a
sensitivity of ≥90% when HPV-16 antibodies were detected in
serum (73).
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TABLE 2 | Summary of proteomics in head and neck neoplasms.





20 Saliva ↑ – (27)
IL-1, IL-6, IL-8, VEGF,
and TNF-α
TSCC 18 Saliva ↑ – (28)
OTHERS







68 Tissue biopsy ↑ – (10)
Adenosine deaminase
(ADA)
TSCC 50 Saliva, blood
sample
↑ – (30)
Midkine HNSCC 103 Blood sample ↑ 57.3% 85.3% – (31)
NFκB-p50 and IκBα HNSCC 104 Blood sample ↑ – (4)





102 Salivary rinse ↑ 62–79% 88–
100%
– (5)
HNSCC, head and neck squamous cell carcinoma; NPC, nasopharyngeal carcinoma; OL, oral leukoplakia; OPSCC, oropharyngeal squamous cell carcinoma; OSCC, oral squamous
cell carcinoma; TSCC, tongue squamous cell carcinoma.
These HPV-related markers do have their limitations as well.
First of all, Kreimer et al. indicate that HPV-P16 E6 seronegative
individuals have a low risk of developing HPV-driven OPC
but that a screening test for these antibodies in the general
population, would still lead to a significant amount of false-
positive results. Thus, identifying the population at risk for
OPSCC would improve the positive predictive value of this
biomarker (73). Another remark, which is also noticed by Wang
et al. and Kreimer et al., is that the published studies consisted of
small study groups and studies with greater statistical power are
required to determine the possibility of using these HPV related
markers in detecting not only neoplasms of the oropharynx, but
also the larynx and hypopharynx (24, 73).
MicroRNA
In the last two decades, altered microRNA expression were
studied in different solid tumors and hematological malignancies.
These microRNAs are single-stranded non-coding RNAs of
17–25 nucleotides that circulate in cell-free body fluids like
blood plasma, serum, saliva, and urine. They can bind
to a complementary site in 3′-untranslated regions of the
messenger RNA (mRNA), thereby negatively regulating the gene
expression via mRNA degradation or translational inhibition.
Some microRNAs are upregulated in cancers and are regarded
as oncogenes. Others are downregulated and are thus presumed
to be tumor suppressor genes. Tumor-derived microRNAs are
also released into the blood and might thus be potential early
cancer detectionmarkers. Furthermore, these microRNA profiles
can be retrieved in a minimally invasive way and they are very
stable, up to 28 days, in serum and plasma when stored at
−20◦C or below (7, 15). There is a plethora of papers that
studied microRNAs, resulting in a large number of microRNAs
that have been identified. MicroRNAs have been studied as a
marker for oral cancer (15, 16) and larynx cancer (7, 17, 74).
Promising results have been observed for a combination of miR-
657 and miR-1287 as a marker for larynx carcinoma with a
sensitivity of 86% and a specificity of 100% (74). Nevertheless, the
result of this study needs to be interpreted with caution, since it
was not yet validated in independent cohorts. The same counts
for all other microRNAs that were under investigation in the
aforementioned studies.
Interferons-Related Genes
The interferons belong to the family of multifunctional cytokines.
These cytokines are produced by host cells in response to
microbial infections and tumor cells. When secreted, they initiate
a cascade through JAK/STAT signaling (Janus Kinases/Signal
Transducer and Activator of Transcription) on their turn
resulting in interferon-stimulated gene upregulation. To date,
more than 400 interferon-stimulated genes have been reported
(18, 19). The first one to be recognized was ISG15 and has
been described in many tumor biopsies from several cancers
including oral squamous cell carcinoma (19). Due to this fact,
it might not be a very specific marker for head and neck
neoplasms. Another candidate gene is the interferon-inducible
transmembrane protein 1 gene (18). The exact mechanism
resulting in overexpression of interferon-stimulated genes in
tumor cells is not yet clarified. Current ongoing studies aim to
identify interferon-stimulated genes in diverse tumors including
oral squamous cell carcinoma (18).
Proteomics
A promising approach to identify biomarkers is the study
of cell proteins, called proteomics (29, 70). Protein markers
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TABLE 3 | Summary of metabolomics in head and neck neoplasms.




(e.g., high glucose, low
lactate, low creatine, high
creatinine, high
choline-creatine ratios etc.)
OSCC 15 Blood sample ↓/↑ – (32)
Plasma and salivary cortisol






A panel of 4 metabolites:
choline, betaine, pipecolinic
acid, L-carnitine
OSCC 30 Saliva ↓/↑ 100% 96.7% 99.7% (34)
Plasma levels of non-anoic
acid, glucose, galactose,
and cysteine + cystine








Salivary glycine and proline OCC 79 Saliva ↓ – (36)
OCC, oral cavity cancer; OL, oral leukoplakia; OPSCC, oropharyngeal squamous cell carcinoma; OSCC, oral squamous cell carcinoma.
TABLE 4 | Summary of glycomics in head and neck neoplasms.
Studied marker Type of tumor No. of patients Sample type Expression Test accuracy indices References
Sens. Spec. Accuracy
GLYCOMICS















Sialic acid, total protein,
total sugar
OSCC 30 Saliva ↑ – (38)
OPC, oropharyngeal cancer; OSCC, oral squamous cell carcinoma.
like carcinoembryonic antigen (CEA), prostate specific antigen
(PSA), alpha-fetoprotein (AFP), and cancer antigen 125 (CA-
125) already earned their place in the diagnosis or progression
of several cancer types (75). In head and neck squamous cell
carcinoma, the following markers have been studied: NFκB-
p50, IκB (4), and the growth factor midkine (31) by blood
sampling, and total salivary protein combined with soluble
CD44 levels (solCD44) in saliva (5). In oral squamous cell
carcinoma, a link has been shown with the protein receptor
for activated C kinase 1 (RACK1) (29). Furthermore, there is
also a place for detection of cytokines in saliva, for example
IL-6 in oral leukoplakia or IL-1, IL-6, IL-8, VEGF, and TNF-
α in tongue squamous cell carcinoma (27, 28). Although some
proteins were put forth as a biomarker for oral squamous cell
carcinoma, several problems limit their clinical utility. First,
there is a substantial heterogeneity of biomarker expression.
Second, some proteins are also expressed in other pathologic
situations such as inflammatory conditions resulting in a low
specificity. Third, different experimental protocols were used
which might explain the discrepancy between the identified



































TABLE 5 | Summary of volatomics in head and neck neoplasms.
Studied marker Type of tumor No. of patients Sample type
(Technique)
Expression Test accuracy indices References
Sens. Spec. Accuracy
VOLATOMICS
2-butanone, ethanol, 2,3-butanediol, 9-tetradecen-1-ol, octane




Ethanol, 2-propenenitrile, undecane HNSCC 22 Breath (GC-MS,
eNose)
↑ (HNSCC vs. HC/benign) (40)
77% 90% 83%
VOC pattern HNSCC 36 Breath (eNose) – HNSCC vs. HC (41)
90% 80% 85%




PTC vs. HC (42)
100 100 100
VOC pattern HNSCC 9 Breath (eNose) – – (43)
Butyric acid, Pentanoic acid, Hexanoic acid, Heptanoic acid Malignant glottis
lesions




VOC pattern HNSCC 52 Breath (eNose) – HNSCC vs. LC (45)
85% 84% 85%





↑ PTC vs. HC (46)
100 100 –
Dibutylhydroxytoluene, dimethyl disulphide,
decamethylcyclopentasiloxane, methyl ethyl ketone, n-heptane,
p-xylene, toluene, I-heptene
OSCC 10 Breath (GC-MS) ↓↑ – (47)
4-chlorobenzene, methanethiol HNC 22 Breath
(eNose/GC-MS)
– HNC vs. LC (48)
100 100 100
VOC pattern HNSCC 100 Breath (eNose) – HNSCC vs. colon cancer (49)
79% 81% 81%
HNSCC vs. bladder cancer
80% 86% 84%
m-cresol, 3-heptanone, benzene, 4-methyl-2-heptanone,
acetone, 1-proanol, non-anal, 4-tert-butylphenol, phenol,
3-methyl-2-heptanone, dimethyltrisulfide, 2-hexanone, ethanoic
acid, furan, hexanal, 2-methyl-5-(methylthio)furan, heptanal,
dimethyldisulfide, 2-methythiophene,
tetrahydro-2,2-dimethyl-5-(1-methyl-1-propenyl)furan,




















































































TABLE 5 | Continued
Studied marker Type of tumor No. of patients Sample type
(Technique)
Expression Test accuracy indices References
Sens. Spec. Accuracy
2-ethyl-5-methylfuran, 3,4-dimethyl-2,5-furanediol,








– 1,4-dichlorobenzene (HNC vs. HC) (51)
100% 100%
1,2-decanediol (HNC vs. HC)
100% 80%
2,5-bis1,1-dimethylethylphenol (HNC vs. HC)
90% 80%
E-3-decen-2-ol (HNC vs. HC)
80% 80%
Hydrogen cyanide HNSCC 23 Breath (SIFT-MS) ↑ Hydrogen cyanide (52)
91% 76%




VOC pattern HNSCC 20 Breath (eNose) – Detection of recurrence (54)
85% 80% 83%
eNose, electronic nose; GC, gas chromatography; HC, healthy controls; HNC, head and neck cancer; HNEC, head and neck epidermoid cancer; HNSCC, head and neck squamous cell carcinoma; LC, lung cancer; MS, mass
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TABLE 6 | Summary of microbiomics in head and neck neoplasms.
Studied marker Type of tumor No. of patients Sample type Expression Test accuracy indices References
Sens. Spec. Accuracy
MICROBIOME
Bacillus, Enterococcus, Parvimonas, Slackia,
and Peptostreptococcus




OSCC 40 Tissue biopsy ↑ – (56)
Lactobacillus and Streptococcus OSCC and
OPSCC
19 Oral rinse ↑ – (57)
Fusobacterium OSCC 4 Tissue biopsy ↑ – (58)
Firmicutes and Actinobacteria Oral cancer 15 Tissue biopsy ↓ – (59)














HNSCC 34 Tissue biopsy ↑
↓






Throat cancer 32 Saliva ↑ – (63)
Streptococcus, Rothia, Porphyromonas,
Bulleidia Fusobacterium, Prevotella, Gemella,
Granulicatella, Peptostreptococcus,
Parvimonas, Peptostreptococcaceae
incertae sedis, Catonella, Treponema,
Selenomonas, Burkholderia
LSCC 29 Tissue biopsy ↓
↑
– (64)
HNSCC, head and neck squamous cell carcinoma; LSCC, laryngeal squamous cell carcinoma: OCC, oral cavity cancer; OPC, oropharyngeal cancer; OPSCC, oropharyngeal squamous
cell carcinoma; OSCC, oral squamous cell carcinoma.
biomarkers (70). Because of the heterogeneity of tumor markers
in different patients, a combination of proteins might again be
a better approach to increase their utility. Although protein
markers seem very promising, there has not yet been identified
a single or a combination of biomarkers to be effective for
clinical use.
Several studies have suggested that autoantibodies that target
specific tumor-associated antigens, could possibly be detected
years before the tumor can be discovered through incidence
screening or radiography (76). During early carcinogenesis,
our immune system tries to remove precancerous lesions by
generating an immune response to specific tumor-associated
antigens (76, 77), which makes them suitable for early detection
of cancer lesions. Besides, autoantibodies are found in serum,
which is favorable for screening. These individual autoantibodies,
however, lack the sensitivity and specificity required for cancer
screening (14, 76).
First of all, some specific tumor-associated antigens can arise
in different types of cancer (e.g., p53) and some of them are
also present in diseases other than cancer, especially autoimmune
diseases (e.g., rheumatoid arthritis, diabetes mellitus type 1,
systemic lupus erythematosus. . . ). They can also be detected in
non-cancer individuals, and because of the heterogenic nature
of cancer, a single autoantibody can only be found in 10–30%
of patients with the same type of cancer. A panel of specific
tumor-associated antigens might hence be the key to raise
sensitivity and specificity (76). As mentioned before, there were
several antibodies to Epstein-Barr virus (EBV) investigated as
a biomarker for the diagnosis of nasopharyngeal carcinoma,
anti-EBV capsid antigen IgA (IgA-VCA), and anti-EA IgG
individually, appeared to have the greatest potential (71). A
combination of IgA-VCA and Epstein-Barr virus DNA load
could minimize false positive cases [(14); Table 2].
Metabolomics
The term metabolome refers to the identification and
quantification of all the small molecule metabolites (<1
kDa) in tissue or biofluids produced during cell metabolism
(36). It is directly linked to cell physiology and thus the result
of both physiological and pathological metabolic processes.
This explains the current use of metabolomics for discovery
of novel biomarkers for cancer diagnosis (36). However, there
are some drawbacks to its use. Because of the high complexity
of the metabolome, interpretation of data is difficult, urging
the use of deep learning and data mining techniques. There is
also a big difference in concentrations ranging for nanomolar
to millimolar. Diet, sex, age, drugs, environment, and lifestyle
might interfere with the metabolite concentration (70). There
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TABLE 7 | Summary of radiomics in head and neck neoplasms.
Imaging technique Type of tumor No. of patients Predictive model Test accuracy indices References
Sens. Spec. Accuracy
CT scan Thyroid nodule 103 Tumor type cytokeratin 19 93% 73% 87% (65)




Ultrasound Thyroid nodule 137 in training set
95 in validation set
Malignant nodules – – 93% (66)
CT scan HNSCC 136 in training set
95 in validation set
Multivariate HNC signature
to predict tumor stage
– – 80% (67)
MRI HNSCC 85 in training set
42 in validation set
Combined T2W and
ceT1W radiomic features
to predict tumor stage
84% 70% 79% (68)
ceT1W radiomic features
to predict tumor stage
80% 67% 75%
HNSCC, head and neck squamous cell carcinoma; HNC, head and neck cancer.
TABLE 8 | Summary of other biomarkers for head and neck neoplasms.
Studied marker Type of tumor No. of patients Sample type Expression Test accuracy indices References
Sens. Spec. Accuracy
Higher mean platelet volume (MPV) PTC 66 Blood sample ↑ 60% 80% 73% (69)
PTC, papillary thyroid carcinoma.
are some papers describing metabolome-related biomarkers in
oral cancer. Bernabe et al. found that the plasma and salivary
cortisol levels were significantly higher in patients with oral
squamous cell carcinoma in comparison with healthy controls
and patients with oral leukoplakia (33). Large validation studies
remain indispensable to confirm the value of metabolites in the
diagnosis of head and neck neoplasms. To date, research on
metabolites as a potential biomarker is still in the discovery phase.
Glycomics
Compared to genomics and proteomics, there is few research
on glycomics. This approach focuses on the modifications of
glycoconjugates related to cancer. Glycolipids and glycoproteins
are glycoconjugates and are important constituents of the
cell membrane. Glycosylation is important in the process of
protein modification and its action relies on the function of
glycosyltransferases and glycosidases in various tissues and cells.
Glycoconjugates are released into the circulation because of
continuously shedding and/or secretion by cancer cells or the
increased cell turnover and could thus be detected in body
fluids to be used as tumor markers. Especially glycoconjugates
in oral cancer, which are in direct contact with saliva, seem to
be promising. The major types of glycosylation are sialylation
and fucosylation, which terminally modify proteins that are
important in the vital biological functions. There have been
reported significantly elevated levels of sialic acid, α-l-fucosidase,
and total protein in oral cancer patients and there is also a link
with oral cancer progression. However, there is need for further
research to determine the role of these biomarkers in oral cancer
development (37, 38).
Volatomics
Volatomics recently emerged as new research field for early
disease diagnosis. This encompasses volatile organic compounds
(VOCs) in nano- to picomolar concentrations, which are the
gaseous end products from endogenous metabolic changes,
digestion,microbiome, inflammation, and oxidative stress. VOCs
can be detected in breath, urine, feces, blood, saliva, skin,
and sweat, and hence, serve as attractive biomarkers, as it is
completely non-invasive, relatively cheap, and provides rapid
results (78). VOCs have already shown clinical potential as
biomarkers for lung (79), gastric (80), breast (81), prostate (82),
andmesothelioma cancer (83), and since carcinogenesis is related
to inflammation and metabolic changes, VOCs could also have
added value as diagnostic biomarkers for head and neck cancer
(Table 5).
The study of VOCs in exhaled breath (breathomics) is
potentially the most important since the sample is unlimitedly
present and sampling causes no side effects for the patient.
Using gas chromatography-mass spectrometry (GC-MS), García
et al. found an increase of 2-butanone, ethanol, 2,3-butanediol,
9-tetradecen-1-ol, and octane, cycloheptane, and cyclononane
derivates in the breath of head and neck cancer patients
compared to healthy controls [(39); Table 5]. The increase
in ethanol was also found in head and neck squamous cell
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carcinoma (HNSCC) patients by Gruber et al., next to 2-
propenenitrile and undecane (40), which discriminated patients
from healthy controls and even patients with benign conditions
with 77% sensitivity and 90% specificity. Hydrogen cyanide was
found to be increased in the breath of HNSCC patients compared
to controls using SIFT-MS and allowed discrimination with 91%
sensitivity and 76% specificity (52).
The VOCs 4-chlorobenzene and methanethiol discriminated
HNSCC patients from lung cancer patients with 100% accuracy
(48), showing potential to use breath analysis for differential
diagnosis, albeit with low study participants and a risk of
overfitting the differentiating models.
Next to spectrometric analysis, VOCs can be detected by
sensor technology [electronic noses (eNoses)] that recognizes the
bulk of VOCs as a breath print, but without identifying individual
VOCs. Using eNoses, HNSCC patients could be differentiated
from controls with sensitivities and specificities ranging between
77–90% and 80–90%, respectively, underlining the difference in
breath print and their use as diagnostic tool (40, 41, 43). Also,
eNoses have shown to be promising for differential diagnosis,
in which the breathprint of HNSCC patients was different from
those with lung cancer, colon cancer and bladder cancer with,
respectively, 85, 79, and 80% sensitivity and 84, 81, and 86%
specificity (45, 49, 54).
Two studies discriminated patients with papillary
thyroid carcinoma (PTC) from healthy controls with both
100% sensitivity and specificity (42). Although one based
this discrimination on an increase of ethyl hexanol, 4-
hydroxybutanoic acid, and a decrease in phenol (42), the
other did not report changes in these compounds (46).
Differences in dibutylhydroxytoluene, dimethyl disulphide,
decamethylcyclopentasiloxane, methyl ethyl ketone, n-heptane,
p-xylene, toluene, I-heptene were found in breath between
patients with oral squamous cell carcinoma and controls (47).
However, based upon VOCs from saliva in these patients, an
increase in 1,3-butanediol and hexadecenoic acid and a decrease
in 2-pentanone and undecane allowed their discrimination from
healthy controls with 96% sensitivity and 95% specificity (53).
This decrease of undecane is in contrast to an increase found in
breath in HNSCC (40) and patients with PTC (46). Furthermore,
saliva analysis of the single VOCs 1,4-dichlorobenzene, 1,2-
decanediol, 2,5-bis1,1-dimethylethylphenol, and E-3-decen-2-ol
allowed to discriminate HNSCC patients from controls with
a sensitivity and specificity between 80–100% and 80–100%,
respectively (51), again being different to VOCs found in exhaled
breath and urine (50).
Lastly, analysis of VOCs from the mucus of 6 patients with
malignant glottic lesions found butyric acid, pentanoic acid,
hexanoic acid, and heptanoic acid to be different compared to
controls (44).
Carcinogenesis is related to an altered metabolism,
upregulated aerobic glycolysis (known as the Warburg effect)
and induces oxidative stress (84, 85). This liberates highly
reactive oxygen species (ROS) which induce lipid peroxidation
of (poly)unsaturated omega-3 and omega-6 fatty acids (PUFA)
in the cellular membranes, mainly generating alkanes and
aldehydes as end products (86). Considering the high number
of hydrocarbons detected in several matrices, this plays a major
role in HNC and therefore, are biomarkers of interest. Aldehydes
are furthermore generated in vivo in signal transduction, genetic
regulation and cellular proliferation. In cancer, an increase in
aldehyde dehydrogenase is seen as malignant cells proliferate.
This causes aldehyde oxidation, resulting in an increased
aldehyde concentration in blood and breath, which is reflected
by the large number of aldehydes found in these matrices.
However, longer chain aldehydes are potentially by-products of
digestion and their origin needs to be explored. Also, several
organic (carboxylic) acids have been found, which are the
main products of proteolysis. Alcohols have 2 major pathways
to be induced in vivo: by ingestion or as product from the
hydrocarbon metabolism by cytochrome P450 enzymes and the
alcohol dehydrogenase activity (86). Alcohols, next to carboxylic
acids, are products of hydrolysis of esters. The cytochrome P450
enzymes hydroxylate lipid peroxidation biomarkers to produce
alcohols, which are found by several studies. Special attention
can be given to phenol: although phenol may be derived from
benzene metabolism, it is most likely to be from exogenous
origin, since it is a by-product of the sampling materials used.
Taken together, it seems that not one VOC is able to accurately
discriminate between several types of head and neck cancer
types and controls. Hence, the combination of several biomarkers
into panels will therefore be key in future research as stressed
by the success of eNoses that react to the bulk of VOCs in
the breath and the success of biomarker panels. However, the
discordance in VOCs can be explained due to a difference in
technology, sampling and by the difference in concentration
range. Furthermore, as with metabolites, the volatilome delivers
high throughput data, complicating the interpretation of the data,
and urging the use of deep learning and data mining techniques.
Next to this, also diet, sex, age, drugs, environment, and lifestyle,
and the microbiome can interfere with the VOC concentration
and induce changes. Hence, the external influence may not be
underestimated. In several trials, ethanol, and 2-propenenitrile
have been identified as possible biomarkers. However, these can
be linked to alcohol abuse and smoking, which are both risk
factors for HNSCC, and could therefore have biased the results
if not corrected for this. Furthermore, the finding that hydrogen
cyanide can serve as biomarker raises concerns about the origin
of this VOC and its correlation with HNSCC since hydrogen
cyanide is known to be released by the microbiome and could
result from exogenous exposure to exhausted fumes and cigarette
smoke. Despite this, it can also be a by-product of cellular
respiration. Hence, for multiple VOCs, their origin and its role
as diagnostic marker remains to be determined.
Microbiomics
The human body is colonized by numerous microbes that
include viruses, bacteria and microbial eukaryotes. Studying
these microbial communities is referred to as “microbiomics”
(64). The microbiome maintains homeostasis and has a dynamic
association with the human host (61, 62). When dysbiosis or
ecological imbalance arises, processes leading to a diseased state
develop (62). Some studies that have already been published,
showed an association between microbiome variations and
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cancer. These studies have demonstrated that the mucosal layers
of the mouth, throat, stomach, and intestines are colonized by
commensal bacteria, which play an important part in normal
human health and can therefore also play a role in the
development of malignancies. For example, Helicobacter pylori
infection can induce gastric cancer through gastric dysbiosis (63).
To date, few has been published about microbiomics as
a (diagnostic) biomarker in head and neck cancer. Most
studies focus on the oral microbiome, which can be used
in the detection of oral cancer, especially oral squamous cell
carcinoma (OSCC) (55). There are many bacterial species in
the oral cavity involved in the genesis of oral cancer which
can be explained through inflammation-induced DNA damage
of epithelial cells caused by endotoxins secreted by these
micro-organisms (55). The link between microorganisms and
head and neck squamous cell carcinoma (HNSCC) is not yet
adequately studied (57). There are some studies that have
detected oral microbial alternations in consumers of alcohol,
tobacco and betel nut. The association between these known
oral cancer risk factors and microbial alterations should be
taken into account (55, 61). It could be possible that the
microbiome helps change an environmental exposure into a
carcinogenic effect (61). Lee et al. studied microbial differences
between oral cancer patients, patients with epithelial precursor
lesions and healthy controls (55). They found a significant
abundance of 5 genera in the salivary microbiome (Bacillus,
Enterococcus, Parvimonas, Slackia, and Peptostreptococcus) of
cancer patients when compared to patients with epithelial
precursor lesions. These changes in the composition of the
microbiome could thus be a potential biomarker for monitoring
the transformation of oral precursor lesions into oral cancer
(55). The use of a microbiome panel (Rothia, Haemophilus,
Corynebacterium, Paludibacter, Porphyromonas, Oribacterium,
and Capnocytophaga) could detect oral cavity cancer and
oropharyngeal cancer by oral rinse with an accuracy of 82% (60).
The association between variations in the human microbiome
and throat cancer has also been studied. Wang et al. studied
microbial markers in the saliva of patients with throat cancer
(hypopharyngeal carcinoma and laryngeal carcinoma) and in the
saliva of patients with vocal cord polyps and healthy controls
(63). They revealed a significant difference in the microbiome
of throat cancer patients vs. patients with vocal cord polyps
and healthy controls. The following genera were found to
be associated with throat cancer: Bacteroides, Pseudomonas,
Ruminiclostridium, and Aggregatibacter. Additionally, they
observed a significant reduction in microbial diversity in
throat cancer patients (63). This reduction in diversity of the
microbiome is also found in other studies concerning oral cancer
(57, 60) and head and neck squamous cell carcinoma (HNSCC)
(62). Zhao et al. on the other hand, observed a greater bacterial
diversity in OSCC tissue when compared to healthy tissue (56).
Table 7 shows potential microbial biomarkers for head and
neck cancer. Few studies have shown that the expression of
Fusobacterium is elevated in the tumor tissue of patients with
OSCC (56, 58) and HNSCC (62).
Although studies of bacteria and their role in carcinogenesis of
colorectal cancer are increasing rapidly, the association between
microbiome and head and neck cancer has not been substantially
studied. The published studies do not specifically focus on early
diagnosis of head and neck neoplasms and have only identified
some potential biomarkers based on difference in expression
between head and neck cancer populations and (healthy)
control populations. These studies also use different sequencing
technologies to measure the abundance of microbiota. There is
need for further, more standardized research before microbial
variations can be considered a diagnostic biomarker for head and
neck neoplasms.
Radiomics
Radiomics comprises the high-throughput mining of advanced
quantitative features to objectively and quantitatively describe
tumor phenotypes. It makes use of standard of care radiologic
images which are subject to advanced mathematical algorithms
to detect tumor characteristics that might be missed by
the radiologist’s eye. This method relies on big data and
supports the clinical decision to diagnose, prognose, and
predict -amongst others- cancer (87). Yip and Aerts extensively
reviewed the applications and limitations of this new -
omics approach (88). We kindly refer to their paper for
detailed information.
In head and neck cancer, radiomics has also entered the
scene. Here, we focus on papers that aimed to diagnose HNC
based on radiomics features. In patients with a thyroid nodule,
a radiomics score (calculated from ultrasound images) was
evaluated against the standard method used for the diagnosis of
thyroid nodules as set by the American College of radiology, the
TI-RADS score. The radiomics score was able to discriminate
malignant from benign nodules with an accuracy of 93% [95%
CI 88.4–97.7%]. The radiomics score performed better compared
to the TI-RADS if scored by junior radiologists (66). In a
similar population, a radiomics predictive model was constructed
based on computer tomography (CT) images which was able
to predict the immunohistochemical characteristics of suspected
thyroid nodules [cytokeratin 19 (AUC 0.87, sensitivity 93%,
and specificity 73%), galectin 3 (AUC 0.85, sensitivity 87%,
and specificity 76%), and thyroperoxidase (AUC 0.84, sensitivity
86%, and specificity 75%)] (65). It seems clear that radiomics
will become a meritorious player in the diagnostic landscape of
thyroid cancer. Given the high prevalence of -largely benign-
thyroid nodules, a good biomarker to discriminate benign from
malignant nodules is indispensable. From the papers published
to date, radiomics seems promising as a biomarker in this field.
Parmar et al. were able to identify 10 radiomic clusters in a
dataset of CT images from 136 patients with HNSCC that were
significantly associated with tumor stage (67). In addition, they
created an HNC signature based on multivariate analysis that
was highly predictive for tumor stage (AUC = 0.80). In a similar
population consisting of 127 HNSCC patients, Ren et al. used
magnetic resonance imaging (MRI) axial fact-suppressed T2-
weighted (T2W) and contrast-enhanced T1-weighted (ceT1W)
images to identify a radiomics signature for preoperative staging
(I-II vs. III-IV). The radiomics signature based on ceT1W
images (AUC 0.853) performed best in discriminating stage I-
II from stage III-IV followed by combined T2W and ceT1W
Frontiers in Oncology | www.frontiersin.org 13 June 2020 | Volume 10 | Article 1020
Konings et al. Biomarkers Head and Neck Neoplasms
images (AUC 0.849) (68). In the training cohort, radiomics
performed better than visual assessment by an experienced
radiologist, however, this was no longer the case in the testing
cohort. In a recent paper of Huang et al., the radiomics’
potential to identify treatment-relevant subtypes of HNSCC was
tested on pretreatment CT scans in a cohort of 113 patients.
Moderate AUC’s varying from 0.71 to 0.79 were observed
in the prediction of HPV positivity, three DNA methylation
subtypes and a mutation of NSD1 in these patients (89).
Radiomics might thus be of additional value to define subtypes
in a non-invasive manner. However, several tumors will be
misclassified based on radiomics alone, making the diagnostic
capacity underperforming.
Besides tumor diagnosis, radiomics is also subject of
investigation in predictive (90–92) and prognostic models (67,
93–96), to evaluate local tumor control (97–99), and HPV status
(100, 101).
A challenge in radiomics remains the fact that the extracted
feature quality is affected by tumor segmentation methods
used to define regions over which to calculate features.
Consistent radiomics analysis across multiple institutions that
use different segmentation algorithms are not obvious. This
is particularly the case for Positron Emission Tomography
(PET), where a limited resolution, a high noise component
related to the limited stochastic nature of the raw data, and
the wide variety of reconstruction options might confound
quantitative feature metrics (102). Standardized scanner
protocols and image reconstruction harmonization are thus
of tremendous importance to make the transfer of radiomics
features possible between institutions. Several papers already
tried to identify the pitfalls of radiomics and the relevant
features that delay interchangeability to make sure that
radiomics becomes a full-fledged biomarker in future cancer
diagnosis (103).
Others
Mean platelet volume (MPV) was found to be significantly higher
in PTC patients when compared to benign goiter patients and
health controls (8.05, 7.57, and 7.36 fl, respectively; p = 000.1;
see Table 8). Moreover, MPV significantly decreased when these
patients were surgically treated [8.05 vs. 7.60 fl; p = 0.005;
(69)]. The quality of this study however was suboptimal. The
study was retrospective and had a relatively small sample size
[n= 66; (69)].
DISCUSSION
In this review, we assessed a large number of potential
biomarkers for the diagnosis of head and neck neoplasms and
included tables providing a detailed overview of the state-of-
the-art investigated biomarkers. All proposed biomarkers have
their advantages and restrictions. Many biomarkers lack the
sensitivity and/or specificity that is required for utilization
in the clinical practice. Therefore, individual biomarkers are
frequently combined into biomarker panels to increase these
diagnostic values.
Furthermore, many studies had a relatively small sample
size and therefore lacked statistical power. Additionally, a great
amount of these studies was retrospective. Larger, prospective
studies should thus be performed in the future. Also, other
elements should be kept in mind when planning future
biomarker research. For example, a considerable part of the
studies that were reviewed included healthy controls as control
population. However, one should recognize that biomarkers in
the clinical practice would be used in patients at risk for certain
types of head and neck neoplasms. Future studies should thus
consider including appropriate patients at risk and/or patients
known with a premalignant lesion when composing their control
population. Most of the described markers have been studied
for one specific type of head and neck neoplasm and can
therefore not be extrapolated to head and neck neoplasms in
general. The diagnostic biomarkers that were reviewed, were
frequently studied in patients from one specific geographical
location. As a consequence, the biomarker might be influenced
by race, genetics, lifestyle, and carcinogenic exposure (104). India
is a high-risk region for the development of oral squamous
cell carcinoma (12, 18, 19, 38). Hence, a biomarker that has
been evaluated in an Indian community might be applicable
only to high-risk regions. The study groups should thus also
investigate this marker in another population that is less at risk
for the occurrence of oral squamous cell carcinoma and study its
applicability worldwide. Also, other variables such as race, eating
habits and environmental exposure should be taken into account.
In this manner, when reviewing the literature, we noticed a large
amount of variability when studying biomarkers for head and
neck cancer. Standardized research would therefore be a necessity
when considering future studies concerning these tumors.
The sampling method of the biomarkers and the analysis of
the specimen also play a determining role in the utilization of the
marker in the clinical practice. For example, saliva and exhaled
breath present an attractive non-invasive alternative to tissue or
serum testing. Serum is easily accessible, relatively cheap, and
can be used in a minimally invasive way, but saliva and breath
offer some other advantages. A non-health practitioner can easily
collect these samples in a non-invasive way, they are easy to store,
the sample cost is relatively low and repeated (unlimited) samples
can easily be acquired because it is a comfortable sampling
method for patients (34, 37).
To our opinion, microRNA, gene hypermethylation, HPV-
related markers, and a panel of proteins seem to be the
biomarkers with the most promising potential of becoming
a diagnostic biomarker for head and neck neoplasms based
on the reported sensitivity, specificity, positive, and negative
predictive values that can be obtained. In certain tumor
types, such as thyroid cancer, also radiomics might become of
importance in the diagnostic landscape and replace invasive
needle biopsies. Hereto, radiomic signatures need to be
identified that are able to discriminate benign from malignant
lesions. A challenge here is to make the radiomic signatures
interchangeable between institutes. Biomarkers studying the
metabolome, glycome, volatilome, and microbiome still need
to be thoroughly investigated before they can be considered
as biomarkers.
Frontiers in Oncology | www.frontiersin.org 14 June 2020 | Volume 10 | Article 1020
Konings et al. Biomarkers Head and Neck Neoplasms
CONCLUSION
Most of the head and neck tumors are diagnosed in an advanced
stage. Hence, besides advancement in treatment of head and
neck neoplasms, early detection of these tumors could play a
significant role in improving the prognosis of these patients.
With this in mind, a lot of research has already been done on
clinically applicable single biomarkers or a panel of biomarkers,
for early detection of head and neck tumors. We reviewed
over 50 markers, all with their advantages and limitations. To
date, a biomarker to diagnose head and neck neoplasms useful
for clinical practice, has not yet been identified nor validated.
Therefore, further research of biomarkers to diagnose head and
neck neoplasms in an early stage is still needed.
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